The cutting-edge progress of immune-checkpoint blockade in lung cancer
F Zhou, M Qiao, C Zhou - Cellular & molecular immunology, 2021 - nature.com
Great advances in immune checkpoint blockade have resulted in a paradigm shift in patients
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …
with lung cancer. Immune-checkpoint inhibitor (ICI) treatment, either as monotherapy or …
Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors
R Bai, Z Lv, D Xu, J Cui - Biomarker research, 2020 - Springer
Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has
ushered in a new era of anti-tumor therapy, with sustained responses and significant …
ushered in a new era of anti-tumor therapy, with sustained responses and significant …
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Diagnosis of tumour type allows prognostication and triage for biomarker testing (see the
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
Supplementary Material Section 3 and Supplementary Figure S1, available at https://doi …
COVID-19 interstitial pneumonia: monitoring the clinical course in survivors
G Raghu, KC Wilson - The Lancet Respiratory Medicine, 2020 - thelancet.com
COVID-19 is an acute respiratory disease caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). Since the first case was identified, 1 the rapid emergence of …
coronavirus 2 (SARS-CoV-2). Since the first case was identified, 1 the rapid emergence of …
Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial
Background Therapeutic blockade of the axis of programmed cell death 1 (PD-1) and its
ligand (PD-L1) has transformed the management of non-small-cell lung cancer (NSCLC) …
ligand (PD-L1) has transformed the management of non-small-cell lung cancer (NSCLC) …
Circulating T-cell immunosenescence in patients with advanced non–small cell lung cancer treated with single-agent PD-1/PD-L1 inhibitors or platinum-based …
Abstract Purpose: CD28, CD57, and KLRG1 have been previously identified as markers of T-
cell immunosenescence. The impact of immunosenescence on anti-PD (L)-1 (ICI) or …
cell immunosenescence. The impact of immunosenescence on anti-PD (L)-1 (ICI) or …
[HTML][HTML] First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special …
NE Ready, C Audigier-Valette… - … for immunotherapy of …, 2023 - ncbi.nlm.nih.gov
Background CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-
based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in …
based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in …
[HTML][HTML] Immunotherapy in older adults with cancer
CJ Presley, F Gomes, CE Burd… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
Cancer is a disease of older adults. The median age at cancer diagnosis is 66 years and
median age at cancer-related death is 72 years. 1 Older adults represent one of the fastest …
median age at cancer-related death is 72 years. 1 Older adults represent one of the fastest …
[HTML][HTML] Effectiveness and safety of immunotherapy in NSCLC patients with ECOG PS score≥ 2–systematic review and meta-analysis
Abstract Background Immune checkpoint inhibitors (ICIs) are standard of care in advanced
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …
non-small cell lung cancer (NSCLC), however their status in patients with poor performance …
Clinical impact of pembrolizumab combined with chemotherapy in elderly patients with advanced non-small-cell lung cancer
K Morimoto, T Yamada, T Yokoi, T Kijima, Y Goto… - Lung Cancer, 2021 - Elsevier
Objectives Combination therapy of immune checkpoint inhibitors and chemotherapy is
considered to be one of the standard treatment options for patients with advanced non-small …
considered to be one of the standard treatment options for patients with advanced non-small …